Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
- PMID: 8594428
- DOI: 10.1056/NEJM199603143341104
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
Abstract
Background: The role of orthotopic liver transplantation in the treatment of patients with cirrhosis and hepatocellular carcinoma is controversial, and determining which patients are likely to have a good outcome after liver transplantation is difficult.
Methods: We studied 48 patients with cirrhosis who had small, unresectable hepatocellular carcinomas and who underwent liver transplantation. In 94 percent of the patients, the cirrhosis was related to infection with hepatitis B virus, hepatitis C virus, or both. The presence of tumor was confirmed by biopsy or serum alpha-fetoprotein assay. The criteria for eligibility for transplantation were the presence of a tumor 5 cm or less in diameter in patients with single hepatocellular carcinomas and no more than three tumor nodules, each 3 cm or less in diameter, in patients with multiple tumors. Thirty-three patients with sufficient hepatic function underwent treatment for the tumor, mainly chemoembolization, before transplantation. After liver transplantation, the patients were followed prospectively for a median of 26 months (range, 9 to 54). No anticancer treatment was given after transplantation.
Results: The overall mortality rate was 17 percent. After four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent. Hepatocellular carcinoma recurred in four patients (8 percent). The overall and recurrence-free survival rates at four years among the 35 patients (73 percent of the total) who met the predetermined criteria for the selection of small hepatocellular carcinomas at pathological review of small hepatocellular carcinomas at pathological review of the explanted liver wer 85 percent and 92 percent, respectively, whereas the rates in the 13 patients (27 percent) whose tumors exceeded these limits were 50 percent and 59 percent, respectively (P=0.01 for overall survival; P=0.002 for recurrence-free survival). In this group of 48 patients with early-stage tumors, tumor-node-metastasis status, the number of tumors, the serum alphafetoprotein concentration, treatment received before transplantation, and 10 other variables were not significantly correlated with survival.
Conclusions: Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis.
Comment in
-
Treating small hepatocellular carcinomas.N Engl J Med. 1996 Mar 14;334(11):728-9. doi: 10.1056/NEJM199603143341112. N Engl J Med. 1996. PMID: 8594436 No abstract available.
-
The quandary over liver transplantation for hepatocellular carcinoma: the greater sin?Liver Transpl. 2002 Sep;8(9):775-7. doi: 10.1053/jlts.2002.35336. Liver Transpl. 2002. PMID: 12200776 No abstract available.
-
Liver Transplant Outcomes After Downstaging to Within Milan Criteria-Balancing Patient Benefit With Resource Allocation.JAMA Surg. 2022 Sep 1;157(9):788-789. doi: 10.1001/jamasurg.2022.2801. JAMA Surg. 2022. PMID: 35857316 No abstract available.
Similar articles
-
Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators.Dig Surg. 2004;21(2):152-9; discussion 159-60. doi: 10.1159/000078741. Epub 2004 May 27. Dig Surg. 2004. PMID: 15166485
-
The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis.PLoS One. 2012;7(12):e50919. doi: 10.1371/journal.pone.0050919. Epub 2012 Dec 7. PLoS One. 2012. Retraction in: PLoS One. 2019 Aug 30;14(8):e0222176. doi: 10.1371/journal.pone.0222176. PMID: 23236406 Free PMC article. Retracted.
-
Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.Hepatology. 1997 Jun;25(6):1485-9. doi: 10.1002/hep.510250629. Hepatology. 1997. PMID: 9185772
-
Treatment strategies for hepatocellular carcinoma in cirrhosis.J Gastrointest Surg. 2003 Mar-Apr;7(3):401-11. doi: 10.1016/s1091-255x(02)00161-0. J Gastrointest Surg. 2003. PMID: 12654567 Review. No abstract available.
-
Current status of liver transplantation for treatment of hepatocellular carcinoma.Dig Dis. 2001;19(4):333-7. doi: 10.1159/000050700. Dig Dis. 2001. PMID: 11935093 Review.
Cited by
-
Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.Cancer Immunol Immunother. 2024 Nov 11;74(1):18. doi: 10.1007/s00262-024-03853-9. Cancer Immunol Immunother. 2024. PMID: 39527136 Free PMC article.
-
Racial and Ethnic Differences in Liver Transplantation and Post-Liver Transplant Survival Among Patients With Hepatocellular Carcinoma.Cancer Med. 2024 Nov;13(21):e70298. doi: 10.1002/cam4.70298. Cancer Med. 2024. PMID: 39506367 Free PMC article.
-
Liver transplantation for hepatocellular carcinoma: a proposal for including preoperative serological indicators improves the Milan criteria expanded.Transl Gastroenterol Hepatol. 2024 Oct 14;9:63. doi: 10.21037/tgh-24-40. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 39503026 Free PMC article.
-
National Liver Cancer Screening Trial (TRACER) study protocol.Hepatol Commun. 2024 Nov 4;8(11):e0565. doi: 10.1097/HC9.0000000000000565. eCollection 2024 Nov 1. Hepatol Commun. 2024. PMID: 39495136 Free PMC article. Clinical Trial.
-
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities.Adv Pharm Bull. 2024 Oct;14(3):513-523. doi: 10.34172/apb.2024.061. Epub 2024 Jul 31. Adv Pharm Bull. 2024. PMID: 39494254 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous